The US updated evidence-based recommendations provide clinicians with comprehensive guidance on when to initiate pharmacologic migraine prevention, how to select an appropriate preventive medication, and how to monitor treatment effectiveness, adverse effects, and medication discontinuation in adults. Developed by a multidisciplinary panel using a systematic review of studies published through June 6, 2024, the guideline integrates evidence from the systematic review, related evidence, principles of care, and evidence-based inferences. The recommendations also address medication selection in specific clinical situations and populations, including patients with fibromyalgia, obesity, or hypertension; older adults; pregnant or lactating patients; sex-related considerations in medication choice; and patients with medication overuse, providing an updated framework for individualized pharmacologic migraine prevention. Source: https://www.neurology.org/
Targeting a systolic blood pressure (BP) of less than 120 mm Hg lowered the incidence…
In patients with type 2 diabetes (T2D) and high cardiovascular risk, targeting a systolic blood…
Among older adults with at least two chronic conditions but no known cardiovascular disease, discontinuing…
Two randomized, placebo-controlled trials of targeted therapies—ziltivekimab, a monoclonal antibody neutralizing interleukin-6, and pelacarsen, an…
Among US Medicare beneficiaries, colder ambient temperatures were associated with increased heart failure hospitalizations while…
In the 10-year extended follow-up of the DECISION-CTO trial, an initial strategy of percutaneous coronary…
This website uses cookies.